Eurozone bond markets signal recession risk amid slowing growthGraphene sensors identify vulnerable brain regions after stroke in miceEl Niño may weaken polar vortex, prompting speculation about summer heat and winter coldRussia cuts cancer programme budget as defence spending reaches post‑Soviet highJournalist Azadeh Moaveni Says Melania Trump Is MisunderstoodValvoline releases October 2026 coupon and promo code listingsLovehoney advertises coupons for toys, lingerie, and gift set discountsGreek tourism officials unveil plans to promote Santorini’s wine, gastronomy and lesser‑known experiencesWe-Vibe Offers Discount Codes Up to 60% OffLowe’s advertises promo codes offering up to $300 off appliancesInstacart promo code offers $15 off in October 2026H&R Block announces 25% discount on DIY tax filing with optional professional reviewHerman Miller Offers Potential Discounts in October 2026Community campaigns across Europe explore new approaches to men's mental healthICE supervisor Brenden Cuni linked to alleged past violence and unlawful arrests
Politifex
Search
Back to event
Federal RegisterGovernmentRegulationHealthcareDrug Approval

Par Health USA LLC, U.S. Agent for PH Health Limited, et al.; Withdrawal of Approval of 37 Abbreviated New Drug Applications

By Health, Drug Administration, Human Services Department, Food · Oct 8, 2026, 11:00 PM CDT

Read full article at Federal Register
The Food and Drug Administration (FDA or Agency) is withdrawing approval of 37 abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

Excerpt shown under fair-use limits. Full text remains with the original publisher.

People in this coverage

Explore their history and attributable record. Being mentioned does not imply endorsement.

Drug Administration →Human Services Department, Food →

Layer 1 · Claims & fact checks

AI analysis

Layer 2 · Biblical perspective

Biblical interpretation
INSUFFICIENT CONTEXT
Read the biblical analysis

Layer 3 · Reporting analysis

AI analysis

Neutral factual statementThe sentence presents a straightforward factual claim about an FDA action.

Neutral factual statementThe sentence reports the applicants' written notification and request without evaluative language.

Context

AI analysis

Missing context

The announcement does not explain why the drug products are no longer marketed, which specific products or companies are involved, the regulatory implications of the withdrawals, or any potential impact on patients and the market.

Important context

The FDA’s withdrawal of ANDA approvals is a regulatory action that occurs when a sponsor indicates that a product is no longer being sold, ensuring the agency’s records reflect current market availability.

Opinion vs. reporting

AI analysis

The text is purely factual reporting without editorial commentary or opinion.